Land: Armenía
Tungumál: enska
Heimild: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
gemcitabine (gemcitabine hydrochloride)
Fareva Unterach GmbH
L01BC05
gemcitabine (gemcitabine hydrochloride)
10mg/ml
concentrate for solution for i/v infusion
glass vial 100ml
Prescription
Registered
2022-11-03
Safety Update: AT_H_0224_001_FI_19-04-03 SPCPIL~3 PRESCRIBING INFORMATION 1. NAME OF THE MEDICINAL PRODUCT GEMCITABINE EBEWE® 10 MG/ML Concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 11.4 mg gemcitabine hydrochloride which corresponds to 10 mg of the active ingredient gemcitabine (10 mg/ml). Each 20 ml vial contains 200 mg gemcitabine (as hydrochloride). Each 50 ml vial contains 500 mg gemcitabine (as hydrochloride). Each 100 ml vial contains 1000 mg gemcitabine (as hydrochloride). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion Product description: clear, colourless to pale yellow solution, free of visible particles. pH: 5.0 – 6.0. Osmolality: 121.7 mOsmol/kg. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. Safety Update: AT_H_0224_001_FI_19-04-03 SPCPIL~3 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Gemcitabine should onl Lestu allt skjalið